Literature DB >> 15188026

Apoptosis and P53, Bcl-2 and Bax gene expression in parathyroid glands of patients with hyperparathyroidism.

Béla Szende1, Parvaneh Farid, Gyula Végso, Ferenc Perner, László Kopper.   

Abstract

Altogether 107 patients were operated on at the Department of Transplantation and Surgery of Semmelweis University in the past four years, for clinical symptoms of hyperparathyroidism. Clinical and laboratory data of the patients supported the diagnosis of primary or secondary hyperparathyroidism. Chronically impaired renal function was found in 52 cases. The removed parathyroid glands showed hyperplasia in 54, adenoma in 50 and carcinoma in 3 cases. The majority of parathyroid lesions in primary hyperparathyroidism were adenomas (41 cases) and in secondary hyperparathyroidism were hyperplasias (43 cases). The ratio of oxyphil to chief cells as well as occasional mitotic and apoptotic figures were determined. The oxyphil component was present in both hyperplastic and tumorous lesions. Apoptosis and mitosis were rarely seen in hyperplasias and adenomas (under 2%), whereas in carcinomas 3% of the tumor cells were apoptotic and 4% showed mitosis. Cytoplasmic p53 positivity could be observed in 3 of the adenomas and in 2 of the hyperplasias. The carcinomas, four adenomas and 3 hyperplasias showed nuclear p53 positivity. Bcl-2 and Bax were detected in the cytoplasm of the tumor cells in the majority of adenomas and in the cells of hyperplasias. Oxyphil cells were more frequently positive than chief cells or clear cells. Colocalization of Bcl-2 and Bax was found randomly in all types of lesions. The very low incidence of carcinoma, the low mitotic and apoptotic ratio in adenomas and hyperplasias suggest a potent antiproliferative defense mechanism in the parathyroid cell population. This may also be reflected in the cytoplasmic colocalization of various gene products which regulate cell death and cell proliferation. No significant differences in the p53, Bcl-2 and Bax spectrum were found between the primary and secondary (i.e. renal failure) parathyroid alterations.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15188026     DOI: 10.1007/BF02893463

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   2.874


  11 in total

1.  Spectrum of hyperparathyroidism.

Authors:  E Reiss; J M Canterbury
Journal:  Am J Med       Date:  1974-06       Impact factor: 4.965

2.  Parathyroid carcinoma. A study of 70 cases.

Authors:  A Schantz; B Castleman
Journal:  Cancer       Date:  1973-03       Impact factor: 6.860

3.  A p53 amino-terminal nuclear export signal inhibited by DNA damage-induced phosphorylation.

Authors:  Y Zhang; Y Xiong
Journal:  Science       Date:  2001-06-08       Impact factor: 47.728

Review 4.  Parathyroid cancer: biology and management.

Authors:  J B Koea; J H Shaw
Journal:  Surg Oncol       Date:  1999-11       Impact factor: 3.279

5.  Parathyroid hyperplasia, adenomas, and carcinomas: differential expression of p27Kip1 protein.

Authors:  L A Erickson; L Jin; P Wollan; G B Thompson; J A van Heerden; R V Lloyd
Journal:  Am J Surg Pathol       Date:  1999-03       Impact factor: 6.394

6.  Parathyroid neoplasms: clinical, histopathological, and tissue microarray-based molecular analysis.

Authors:  Alexander Stojadinovic; Axel Hoos; Aviram Nissan; Maria E Dudas; Carlos Cordon-Cardo; Ashok R Shaha; Murray F Brennan; Bhuvanesh Singh; Ronald A Ghossein
Journal:  Hum Pathol       Date:  2003-01       Impact factor: 3.466

7.  DNA content of parathyroid tumors.

Authors:  J Bocsi; F Perner; J Szücs; E Glaz; L Kopper
Journal:  Anticancer Res       Date:  1998 Jul-Aug       Impact factor: 2.480

8.  P53 as a marker of differentiation between hyperplastic and adenomatous parathyroids.

Authors:  Francesca Ricci; Pietro Luigi Mingazzini; Valeria Sebastiani; Emilio D'Erasmo; Claudio Letizia; Giorgio De Toma; Piero Luigi Alò
Journal:  Ann Diagn Pathol       Date:  2002-08       Impact factor: 2.090

9.  Mitotic activity in benign parathyroid disease.

Authors:  D C Snover; K Foucar
Journal:  Am J Clin Pathol       Date:  1981-03       Impact factor: 2.493

10.  Proliferative activity in parathyroid tumors as detected by Ki-67 immunostaining.

Authors:  G C Abbona; M Papotti; G Gasparri; G Bussolati
Journal:  Hum Pathol       Date:  1995-02       Impact factor: 3.466

View more
  6 in total

1.  Molecular profiling of parathyroid hyperplasia, adenoma and carcinoma.

Authors:  Kristóf Árvai; Katalin Nagy; Helga Barti-Juhász; István Peták; Tibor Krenács; Tamás Micsik; Gyula Végső; Ferenc Perner; Béla Szende
Journal:  Pathol Oncol Res       Date:  2011-12-24       Impact factor: 3.201

Review 2.  Expression of p53, Ki-67 and Bcl-2 in parathyroid adenoma and residual normal tissue.

Authors:  Tuvia Hadar; Jacob Shvero; Eitan Yaniv; Eduard Ram; Itzhak Shvili; Rumelia Koren
Journal:  Pathol Oncol Res       Date:  2005-03-31       Impact factor: 3.201

3.  Does vitamin D receptor and calcium receptor activation therapy play a role in the histopathologic alterations of parathyroid glands in refractory uremic hyperparathyroidism?

Authors:  Carlo Lomonte; Luigi Vernaglione; Domenico Chimienti; Andrea Bruno; Savino Cocola; Annalisa Teutonico; Francesco Cazzato; Carlo Basile
Journal:  Clin J Am Soc Nephrol       Date:  2008-03-05       Impact factor: 8.237

Review 4.  Parathyroid Pathology.

Authors:  Julie Guilmette; Peter M Sadow
Journal:  Surg Pathol Clin       Date:  2019-09-27

5.  Expression of p53, Ki67, epidermal growth factor receptor, transforming growth-factorα, and p21 in primary and secondary hyperparathyroidism.

Authors:  Saime Paydas; Arbil Acikalim; Bulent Kaya; Bermal Hasbay Bicer; Mehmet Ulker; Orhan Demircan; Aysun Uguz; Mustafa Balal; Gurhan Sakman; Yasar Sertdemir; Refika Karaer; Eda Altun
Journal:  Indian J Endocrinol Metab       Date:  2014-11

6.  Role of Ca²⁺ in Inhibiting Ischemia-Induced Apoptosis of Parathyroid Gland Cells in New Zealand White Rabbits.

Authors:  Wei-Han Cao; Yan-Jun Su; Nian-Qiu Liu; Ying Peng; Chang Diao; Ruo-Chuan Cheng
Journal:  Med Sci Monit       Date:  2020-02-19
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.